Clinical trial
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With…
NCT00436163 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00436163 |
|---|---|
| Title | A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B |
| Official title | Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Chronic |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a |
| Enrollment | 39 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Feb 16, 2007 |
| Last update posted | Oct 24, 2016 |
| Countries | Estonia, Latvia, Lithuania |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: